STAA May 2024 65.000 call
| Previous Close | 0.2300 |
| Open | 0.2300 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 65.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.2300 - 0.2300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 177 |
Business WireSTAAR Surgical to Report First Quarter Results on May 7, 2024
LAKE FOREST, Calif., April 29, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
Investor's Business DailyStaar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating
Staar Surgical stock had its Relative Strength (RS) Rating upgraded from 80 to 84 Thursday. This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against other publicly traded companies. Is Staar Surgical Stock A Buy?
ZacksStrength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
